Back to Search
Start Over
Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients.
- Source :
- Journal of Translational Medicine; 3/11/2020, Vol. 18 Issue 1, p1-10, 10p
- Publication Year :
- 2020
-
Abstract
- <bold>Background: </bold>PD-1 blocking agents, such as nivolumab, have demonstrated clear anti-tumor effects and clinical benefits in a subset of patients with advanced malignancies. Nonetheless, more efforts are needed to identify reliable biomarkers for outcome, to correctly select patients who will benefit from anti-PD-1 treatment. The aim of this study was to investigate the role of peripheral CD8+T cells expressing CD73, involved in the generation of the immune suppressive molecule adenosine, in predicting outcome after nivolumab treatment in advanced melanoma patients.<bold>Methods: </bold>PBMCs from 100 melanoma patients treated with nivolumab were collected at National Cancer Institute "G. Pascale" of Naples. Frequencies of CD8+ lymphocytes phenotypes were assessed by flow cytometry at baseline before nivolumab treatment, along with clinical characteristics and blood count parameters. Healthy controls (n = 20) were also analysed. Percentages of baseline T cells expressing PD-1 and CD73 were correlated with outcome after nivolumab treatment.<bold>Results: </bold>Melanoma patients presented a lower frequency of total circulating CD8+ lymphocytes than control subjects (p = 0.008). Patients with low baseline percentage of circulating CD8+PD-1+CD73+ lymphocytes (< 2.3%) had better survival (22.4 months vs 6.9 months, p = 0.001). Patients (39%) with clinical benefit from nivolumab therapy presented a significantly lower frequency of circulating CD8+PD-1+CD73+ lymphocytes than patients who progressed to nivolumab treatment (p = 0.02).<bold>Conclusions: </bold>Our observations suggest that baseline CD73 expression on circulating CD8+PD-1+ lymphocytes appear a promising biomarker of response to anti-PD-1 treatment in melanoma patients. Further investigations are needed for validation and for clarifying its role as prognostic or predictive marker. [ABSTRACT FROM AUTHOR]
- Subjects :
- MELANOMA
T cells
FLOW cytometry
BRAF genes
LYMPHOCYTES
CELLS
INTERLEUKIN-7
Subjects
Details
- Language :
- English
- ISSN :
- 14795876
- Volume :
- 18
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Journal of Translational Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 142185061
- Full Text :
- https://doi.org/10.1186/s12967-020-02285-0